NRX Pharmaceuticals (NRXP) Other financing activities (2018 - 2025)

NRX Pharmaceuticals (NRXP) has 6 years of Other financing activities data on file, last reported at $3.1 million in Q4 2025.

• On a quarterly basis, Other financing activities rose 61.88% year-over-year to $3.1 million in Q4 2025; TTM through Dec 2025 was $3.1 million, a 22.16% decrease from a year earlier, with the FY2025 full-year figure at $3.1 million, down 22.16% from the prior year.
• Other financing activities for Q4 2025 stood at $3.1 million, up from $1.9 million in the prior quarter.
• Over the last five years, Other financing activities for NRXP reached as high as $9.2 million in Q3 2021 and fell as low as -$5.6 million in Q4 2021.
• Historically, Other financing activities has averaged $2.7 million across 3 years, with a median of $2.5 million in 2024.
• Across the five-year window, Other financing activities jumped 600.84% in 2021 and soared 61.88% in 2025, its largest moves.
• Year by year, Other financing activities stood at -$5.6 million in 2021, then surged by 133.75% to $1.9 million in 2024, then surged by 61.88% to $3.1 million in 2025.
• Per Business Quant data, the three most recent Other financing activities figures were $3.1 million in Q4 2025, $1.9 million in Q4 2024, and $1.0 million in Q3 2024.